Michael Stratton

Source: Wikipedia, the free encyclopedia.
This article is about the cancer researcher. For the American football player, see Mike Stratton.

Haberdashers' Aske's Boys' School
Alma materUniversity of Oxford (BM BCh)
University of London (PhD)[9]
Known for
Spouse
Judith Breuer
​
(m. 1981)​
[3]
Awards
Institute of Cancer Research
Guy's Hospital
University of Oxford[3]
ThesisRole of genetic alterations in the genesis of human soft tissue tumours and medulloblastoma (1990)
Doctoral studentsNazneen Rahman[4][5][6][7]
Ludmil Alexandrov[8]
Websitesanger.ac.uk/research/faculty/mstratton

Sir Michael Rudolf Stratton,

Wellcome Trust Sanger Institute. He currently heads the Cancer Genome Project and is a leader of the International Cancer Genome Consortium.[10][11][12][13][14][15][16][17][18][19]

Education

Stratton was educated at the independent

Institute of Cancer Research, awarded by the University of London in 1990.[9]

Career and research

Stratton has held clinical posts at

Institute of Cancer Research. He joined the Sanger Institute in 2000 and was promoted to deputy director in 2007. In May 2010, he was appointed director, succeeding Allan Bradley.[20]

Stratton's research interests

Wilms tumour and Peutz–Jeghers syndrome.[33]

At the announcement of the completion of the

malignant melanomas and 4 per cent of non-small-cell lung cancers respectively.[33]

In 2009, Stratton and colleagues reported the first complete cancer genomes, from a lung tumour and a melanoma.[29][38] They also analysed the genomes from 24 different breast tumours and found a diversity of DNA abnormalities, indicating that cancers can be divided in more subcategories than previously thought.[38][39] Stratton's team maintain the Catalogue of Somatic Mutations in Cancer (COSMIC) database, a set of online resources available to the scientific community.[40] He is also one of the lead researchers in the International Cancer Genome Project, a £600 million, multi-national project to sequence 25 000 cancer genomes, from 50 different types of cancer.[33] Stratton's research has been funded by the Wellcome Trust and the Medical Research Council (MRC).[41]

Controversy

In August 2018 it was reported that an investigation was under way into allegations of bullying of staff and gender discrimination made against senior management of the

Wellcome Trust Sanger Institute, including Stratton.[42] The independent investigation, carried out by the barrister Thomas Kibling from Matrix Chambers, concluded in October 2018 and cleared Stratton of any wrongdoing.[citation needed] The public report stated that the allegation of bullying was "misplaced, unwarranted and misconceived", while also listing areas for improvement in the workings of the Sanger Institute.[43][44] Some of the claimants disputed these findings.[45]

Awards and honours

Stratton was elected a Fellow of the Academy of Medical Sciences (FMedSci) in 1999, elected a Fellow of the Royal Society in 2008, elected to EMBO Membership in 2009[1] and was awarded the Lila Gruber Cancer Research Award in 2010. He was knighted in the 2013 Birthday Honours for services to medical science.[46][47] His nomination for the Royal Society reads:

Michael Stratton is distinguished for his contributions to the genetics of human cancer. Using genetic linkage studies and positional cloning, he mapped and isolated the breast cancer susceptibility gene BRCA2 and subsequently other cancer predisposition genes: CYLD and STK11. To provide a new approach to find cancer genes he promoted the notion of large scale systematic searches of the human genome for somatic mutations in cancer and initiated the Cancer Genome Project leading to the discovery of BRAF as a melanoma gene. His work has important implications for the understanding of the genetic mechanisms underlying cancer, diagnosis and therapy.[48]

In May 2022, Stratton was awarded the inaugural 'In Search of Wonder Lifetime Achievement Award' at the Cambridge Independent's Science and Technology Awards, sponsored by Waterbeach creative design agency JDJ Creative.[49] He received the award at a ceremony held at the Wellcome Genome Campus, just three months after announcing his decision to step down as director of the Wellcome Sanger Institute and CEO of the Wellcome Genome Campus after 12 years in the post.[50]

References

  1. ^ a b "EMBO welcomes 66 leading life scientists as members". biochemist.org. Archived from the original on 17 August 2014.
  2. ^ Louis-Jeantet Prize
  3. ^
    doi:10.1093/ww/9780199540884.013.U36509. (Subscription or UK public library membership
    required.)
  4. EThOS uk.bl.ethos.314056
    .
  5. ^ "Royal Marsden: Professor Nazneen Rahman". Archived from the original on 2 February 2015.
  6. S2CID 19914321
    .
  7. S2CID 7082835
    .
  8. EThOS uk.bl.ethos.708130
    .
  9. ^
    OCLC 940324613
    .
  10. ^ Michael Stratton's publications indexed by the Scopus bibliographic database. (subscription required)
  11. ^ Michael Stratton's publications in Google Scholar
  12. PMID 20393554
    .
  13. PMID 20103622
    .
  14. PMID 14993899
    .
  15. S2CID 9095109
    .
  16. S2CID 4400728
    .
  17. ^ Patterns of mutation in human cancer genomes – video of a seminar given by Stratton at the Royal Society.
  18. Today Programme
  19. ^ "Feature: Professor Mike Stratton – how I got into cancer genetics 'Wellcome News' issue 66". 2011. Archived from the original on 20 March 2012.
  20. ^ "Professor Mike Stratton appointed new Director". Wellcome Trust Sanger Institute. Archived from the original on 2 February 2013.
  21. Microsoft Academic
  22. PMID 9579822
    .
  23. PMID 9063750
    .
  24. PMID 9002670
    .
  25. S2CID 26808443
    .
  26. PMID 11902570
    .
  27. PMID 8091231
    .
  28. S2CID 4346791
    .
  29. ^ a b c Chrissie Giles (24 June 2010). "Great expectations: human genome research". Wellcome News. Wellcome Trust. Retrieved 24 June 2010.
  30. S2CID 195216803
    .
  31. S2CID 2909283
    .
  32. PMID 17200668
    .
  33. ^ a b c "Mike Stratton". Wellcome Trust Sanger Institute Website. Wellcome Trust Sanger Institute. Retrieved 24 June 2010.
  34. PMID 17554300
    .
  35. ^ Karen Hopkin (1 June 2009). "On the MAP". The Scientist. Retrieved 24 June 2010.
  36. S2CID 3071547
    .
  37. S2CID 4313058
    .
  38. ^ a b Mark Henderson (24 December 2009). "Breast cancer is not a single disease, scientists discover". The Times. Retrieved 24 June 2010.
  39. PMID 20033038
    .
  40. PMID 19906727
    .
  41. ^ "UK Government research grants awarded to Michael Stratton". Research Councils UK. Archived from the original on 15 April 2015.
  42. ^ Marsh, Sarah; Devlin, Hannah (29 August 2018). "Bosses at leading UK science institute accused of bullying staff". The Guardian. Retrieved 29 August 2018.
  43. ^ "Result of independent investigation into whistleblowing allegations released". Sanger Institute. 31 October 2018. Retrieved 31 October 2018.
  44. ^ Thomas Kibling (31 October 2018). "Thomas Kibling's Investigatory Report" (PDF). Sanger Institute. Retrieved 31 October 2018.
  45. S2CID 53305689
    .
  46. ^ "No. 60534". The London Gazette (Supplement). 15 June 2013. p. 2.
  47. ^ Michael Stratton, cancer gene scientist, knighted, BBC News, 14 June, 3013
  48. ^ "EC/2008/40: Stratton, Michael Rudolf". London: The Royal Society. Archived from the original on 20 January 2014.
  49. ^ "Winners of the Cambridge Independent Science and Technology Awards 2022 revealed". Cambridge Independent. 11 May 2022. Retrieved 25 August 2022.
  50. ^ "Cancer genetics pioneer Professor Sir Mike Stratton to step down as Wellcome Sanger Institute director". Cambridge Independent. 4 February 2022. Retrieved 25 August 2022.
Non-profit organization positions
Preceded by
Wellcome Trust Sanger Institute

2010–2023 		Succeeded by
Retrieved from "https://en.wikipedia.org/w/index.php?title=Michael_Stratton&oldid=1190742338"